Ontology highlight
ABSTRACT: Background
Oral oxybutynin has been associated with the development of cognitive impairment.Objective
The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) in older adults with documented cognitive impairment.Methods
This is a population-based retrospective analysis of antimuscarinic new users aged ≥ 66 years from January 2008 to December 2011 (n = 42,886) using a 5% random sample of Medicare claims linked with Part D data. Cognitive impairment was defined as a diagnosis of mild cognitive impairment, dementia, use of antidementia medication, and memory loss/drug-induced cognitive conditions in the year prior to the initial antim
SUBMITTER: Vouri SM
PROVIDER: S-EPMC5904003 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature